Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era
Oluwaseun Falade‐Nwulia(Johns Hopkins University), Shruti H. Mehta(Johns Hopkins University), Carl A. Latkin(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Alana Merkow(Johns Hopkins University)
Cited by 104
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694